Apr 30, 2018   SOURCE: PR NewsWire

Fungal Foot Infections Drug Development Pipeline Review 2018

Fungal Foot Infections Drug Development Pipeline Review 2018

DUBLIN, April 30, 2018 /PRNewswire/ --

The "Fungal Foot Infections Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Fungal Foot Infections Drug Development Pipeline Review, 2018 provides an overview of the onychomycosis (Tinea unguium) and athlete's foot (Tinea pedis) pipeline landscapes. The report provides comprehensive information on the therapeutics under development and key players active in these two indications, and features dormant and discontinued projects.

Onychomycosis and athlete's foot are nonlife-threatening fungal infections that most commonly affect the toenails and the feet respectively. Athlete's foot affects 15% of the population globally, with males being more commonly affected than females. Onychomycosis affects roughly 10% of the global adult population.

There is considerable overlap in both the development of pipeline products and existing marketed products between the two indications, which reflects similarities in the underlying pathophysiology.

There are a total of 25 products in development across these indications, by 24 companies.

Scope

    --  Which companies are the most active within each pipeline?
    --  Which pharmaceutical approaches are the most prominent at each stage of
        the pipeline and within each indication?
    --  To what extent do universities and institutions play a role within this
        pipeline, compared with pharmaceutical companies?
    --  What are the most important R&D milestones and data publications to have
        happened in this disease area?

Key Topics Covered:

1 Introduction
1.1 Fungal Foot Infections Report Coverage
1.2 Onychomycosis (Tinea Unguium) - Overview
1.3 Tinea pedis (Athlete Foot) - Overview

2 Therapeutics Development
2.1 Onychomycosis (Tinea Unguium)
2.2 Tinea pedis (Athlete Foot)

3 Therapeutics Assessment
3.1 Onychomycosis (Tinea Unguium)
3.2 Tinea pedis (Athlete Foot)

4 Companies Involved in Therapeutics Development
4.1 Onychomycosis (Tinea Unguium)
4.2 Tinea pedis (Athlete Foot)

5 Dormant Projects
5.1 Onychomycosis (Tinea Unguium)
5.2 Tinea pedis (Athlete Foot)

6 Discontinued Products
6.1 Onychomycosis (Tinea Unguium)

7 Product Development Milestones
7.1 Onychomycosis (Tinea Unguium)
7.2 Tinea pedis (Athlete Foot)

8 Appendix

Companies Mentioned 

    --  Almirall SA
    --  Astellas Pharma Inc
    --  Biolab Farmaceutica Ltda
    --  Blueberry Therapeutics Ltd
    --  Broda Tech LLC
    --  Dermala Inc
    --  Eisai Co Ltd
    --  Helix BioMedix Inc
    --  Hexima Ltd
    --  Kaken Pharmaceutical Co Ltd
    --  Meiji Seika Pharma Co Ltd
    --  Moberg Pharma AB
    --  NAL Pharmaceuticals Ltd
    --  Novabiotics Ltd
    --  Novan Inc
    --  Novoteris LLC
    --  Onychomycosis (Tinea Unguium)
    --  Sanotize Research And Development Corp
    --  Tinea pedis (Athlete Foot)
    --  Viamet Pharmaceuticals Inc

For more information about this report visit https://www.researchandmarkets.com/research/vqhm57/fungal_foot?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/fungal-foot-infections-drug-development-pipeline-review-2018-300638982.html

SOURCE Research and Markets